Blood Cancer Drugs - Global Top Players Market Share and Ranking 2026- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Blood Cancer Drugs - Global Top Players Market Share and Ranking 2026

Blood Cancer Drugs - Global Top Players Market Share and Ranking 2026

Publication Date: 2026-04-06
Report Id: 3097426
Industry: Pharma & Healthcare
Report Page: 101
Chart: 105

PDF Download

Publication Date: 2026-04-06
Report Id: 3097426
Industry: Pharma & Healthcare
Report Page: 101
Chart: 105

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Blood Cancer Drugs Definition
1.2 Global Blood Cancer Drugs Market Size and Forecast
1.3 Japan Blood Cancer Drugs Market Size and Forecast
1.4 Share of Japan Blood Cancer Drugs Market with Respect to the Global Market
1.5 Blood Cancer Drugs Market Size: Japan VS Global Growth Rate, 2021-2032
1.6 Blood Cancer Drugs Market Dynamics
1.6.1 Blood Cancer Drugs Market Drivers
1.6.2 Blood Cancer Drugs Market Restraints
1.6.3 Blood Cancer Drugs Industry Trends
1.6.4 Blood Cancer Drugs Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Blood Cancer Drugs, Global Market Share by Company, 2021-2026
2.2 Global Blood Cancer Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Blood Cancer Drugs Concentration Ratio
2.4 Global Blood Cancer Drugs Mergers & Acquisitions, Expansion Plans
2.5 Global Blood Cancer Drugs Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 Japan Leading Players, Market Share and Ranking
3.1 By Revenue of Blood Cancer Drugs, Japan Market Share by Company, 2021-2026
3.2 Japan Blood Cancer Drugs Blood Cancer Drugs Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Blood Cancer Drugs Industry Chain
4.2 Blood Cancer Drugs Upstream Analysis
4.2.1 Blood Cancer Drugs Core Raw Materials
4.2.2 Main Manufacturers of Blood Cancer Drugs Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Blood Cancer Drugs Production Mode
4.6 Blood Cancer Drugs Procurement Model
4.7 Blood Cancer Drugs Industry Sales Model and Sales Channels
4.7.1 Blood Cancer Drugs Sales Model
4.7.2 Blood Cancer Drugs Typical Distributors

5 Sights Blood Cancer Drugs Market Classification
5.1 Blood Cancer Drugs Classification by Type
5.1.1 Targeted Therapy
5.1.2 Chemotherapy
5.1.3 Immunotherapy
5.1.4 Other
5.1.5 by Type, Global Blood Cancer Drugs Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.1.6 by Type, Global Blood Cancer Drugs Consumption Value, 2021-2032
5.2 Blood Cancer Drugs Classification by Route of Administration
5.2.1 Oral
5.2.2 Injection
5.2.3 Others
5.2.4 by Route of Administration, Global Blood Cancer Drugs Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.2.5 by Route of Administration, Global Blood Cancer Drugs Consumption Value, 2021-2032
5.3 Blood Cancer Drugs Classification by Sales Channel
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Other
5.3.4 by Sales Channel, Global Blood Cancer Drugs Consumption Value & CAGR, 2021 VS 2025 VS 2032
5.3.5 by Sales Channel, Global Blood Cancer Drugs Consumption Value, 2021-2032

6 Sights by Application
6.1 Blood Cancer Drugs Segment by Application
6.1.1 Leukemia
6.1.2 lymphoma
6.1.3 Multiple Myeloma
6.2 by Application, Global Blood Cancer Drugs Consumption Value & CAGR, 2021 VS 2025 VS 2032
6.3 by Application, Global Blood Cancer Drugs Consumption Value, 2021-2032

7 Sales Sights by Region
7.1 By Region, Global Blood Cancer Drugs Consumption Value, 2021 VS 2025 VS 2032
7.2 By Region, Global Blood Cancer Drugs Consumption Value, 2021-2032
7.3 North America
7.3.1 North America Blood Cancer Drugs Market Size & Forecasts, 2021-2032
7.3.2 By Country, North America Blood Cancer Drugs Market Size Market Share
7.4 Europe
7.4.1 Europe Blood Cancer Drugs Market Size & Forecasts, 2021-2032
7.4.2 By Country, Europe Blood Cancer Drugs Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Blood Cancer Drugs Market Size & Forecasts, 2021-2032
7.5.2 By Country/Region, Asia Pacific Blood Cancer Drugs Market Size Market Share
7.6 South America
7.6.1 South AmericaBlood Cancer Drugs Market Size & Forecasts, 2021-2032
7.6.2 By Country, South America Blood Cancer Drugs Market Size Market Share
7.7 Middle East & Africa

8 Sales Sights by Country Level
8.1 By Country, Global Blood Cancer Drugs Market Size & CAGR, 2021 VS 2025 VS 2032
8.2 By Country, Global Blood Cancer Drugs Consumption Value, 2021-2032
8.3 United States
8.3.1 United States Blood Cancer Drugs Market Size, 2021-2032
8.3.2 by Type, United States Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.3.3 by Application, United States Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.4 Europe
8.4.1 Europe Blood Cancer Drugs Market Size, 2021-2032
8.4.2 by Type, Europe Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.4.3 by Application, Europe Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.5 China
8.5.1 China Blood Cancer Drugs Market Size, 2021-2032
8.5.2 by Type, China Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.5.3 by Application, China Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.6 Japan
8.6.1 Japan Blood Cancer Drugs Market Size, 2021-2032
8.6.2 by Type, Japan Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.6.3 by Application, Japan Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.7 South Korea
8.7.1 South Korea Blood Cancer Drugs Market Size, 2021-2032
8.7.2 by Type, South Korea Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.7.3 by Application, South Korea Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.8 Southeast Asia
8.8.1 Southeast Asia Blood Cancer Drugs Market Size, 2021-2032
8.8.2 by Type, Southeast Asia Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.8.3 by Application, Southeast Asia Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.9 India
8.9.1 India Blood Cancer Drugs Market Size, 2021-2032
8.9.2 by Type, India Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.9.3 by Application, India Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.10 Middle East & Africa
8.10.1 Middle East & Africa Blood Cancer Drugs Market Size, 2021-2032
8.10.2 by Type, Middle East & Africa Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032
8.10.3 by Application, Middle East & Africa Blood Cancer Drugs Consumption Value Market Share, 2025 VS 2032

9 Company Profile
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Company Information, Head Office, Market Area, and Industry Position
9.1.2 Bristol-Myers Squibb Company Profile and Main Business
9.1.3 Bristol-Myers Squibb Blood Cancer Drugs Models, Specifications, and Application
9.1.4 Bristol-Myers Squibb Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.1.5 Bristol-Myers Squibb Recent Developments
9.2 Johnson & Johnson
9.2.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
9.2.2 Johnson & Johnson Company Profile and Main Business
9.2.3 Johnson & Johnson Blood Cancer Drugs Models, Specifications, and Application
9.2.4 Johnson & Johnson Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.2.5 Johnson & Johnson Recent Developments
9.3 AbbVie
9.3.1 AbbVie Company Information, Head Office, Market Area, and Industry Position
9.3.2 AbbVie Company Profile and Main Business
9.3.3 AbbVie Blood Cancer Drugs Models, Specifications, and Application
9.3.4 AbbVie Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.3.5 AbbVie Recent Developments
9.4 Novartis
9.4.1 Novartis Company Information, Head Office, Market Area, and Industry Position
9.4.2 Novartis Company Profile and Main Business
9.4.3 Novartis Blood Cancer Drugs Models, Specifications, and Application
9.4.4 Novartis Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.4.5 Novartis Recent Developments
9.5 Roche
9.5.1 Roche Company Information, Head Office, Market Area, and Industry Position
9.5.2 Roche Company Profile and Main Business
9.5.3 Roche Blood Cancer Drugs Models, Specifications, and Application
9.5.4 Roche Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.5.5 Roche Recent Developments
9.6 Amgen
9.6.1 Amgen Company Information, Head Office, Market Area, and Industry Position
9.6.2 Amgen Company Profile and Main Business
9.6.3 Amgen Blood Cancer Drugs Models, Specifications, and Application
9.6.4 Amgen Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.6.5 Amgen Recent Developments
9.7 Takeda
9.7.1 Takeda Company Information, Head Office, Market Area, and Industry Position
9.7.2 Takeda Company Profile and Main Business
9.7.3 Takeda Blood Cancer Drugs Models, Specifications, and Application
9.7.4 Takeda Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.7.5 Takeda Recent Developments
9.8 Pfizer
9.8.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
9.8.2 Pfizer Company Profile and Main Business
9.8.3 Pfizer Blood Cancer Drugs Models, Specifications, and Application
9.8.4 Pfizer Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.8.5 Pfizer Recent Developments
9.9 AstraZeneca
9.9.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
9.9.2 AstraZeneca Company Profile and Main Business
9.9.3 AstraZeneca Blood Cancer Drugs Models, Specifications, and Application
9.9.4 AstraZeneca Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.9.5 AstraZeneca Recent Developments
9.10 Gilead Sciences
9.10.1 Gilead Sciences Company Information, Head Office, Market Area, and Industry Position
9.10.2 Gilead Sciences Company Profile and Main Business
9.10.3 Gilead Sciences Blood Cancer Drugs Models, Specifications, and Application
9.10.4 Gilead Sciences Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.10.5 Gilead Sciences Recent Developments
9.11 Sanofi
9.11.1 Sanofi Company Information, Head Office, Market Area, and Industry Position
9.11.2 Sanofi Company Profile and Main Business
9.11.3 Sanofi Blood Cancer Drugs Models, Specifications, and Application
9.11.4 Sanofi Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.11.5 Sanofi Recent Developments
9.12 Incyte Corporation
9.12.1 Incyte Corporation Company Information, Head Office, Market Area, and Industry Position
9.12.2 Incyte Corporation Company Profile and Main Business
9.12.3 Incyte Corporation Blood Cancer Drugs Models, Specifications, and Application
9.12.4 Incyte Corporation Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.12.5 Incyte Corporation Recent Developments
9.13 BeiGene
9.13.1 BeiGene Company Information, Head Office, Market Area, and Industry Position
9.13.2 BeiGene Company Profile and Main Business
9.13.3 BeiGene Blood Cancer Drugs Models, Specifications, and Application
9.13.4 BeiGene Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.13.5 BeiGene Recent Developments
9.14 Astellas Pharma
9.14.1 Astellas Pharma Company Information, Head Office, Market Area, and Industry Position
9.14.2 Astellas Pharma Company Profile and Main Business
9.14.3 Astellas Pharma Blood Cancer Drugs Models, Specifications, and Application
9.14.4 Astellas Pharma Blood Cancer Drugs Revenue and Gross Margin, 2021-2026
9.14.5 Astellas Pharma Recent Developments

10 Conclusion

11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer

According to YH Research, the global market for Blood Cancer Drugs should grow from US$ 79325 million in 2025 to US$ 143099 million by 2032, with a CAGR of 8.6% for the period of 2026-2032.

Blood cancer drugs are a class of medications used for the prevention, control, or treatment of malignant diseases of the hematologic system, including leukemia, lymphoma, multiple myeloma, and other related blood cancers. These drugs include chemotherapeutic agents, targeted therapies, immunomodulators, and cell-based immunotherapies, working through mechanisms such as inhibition of cancer cell proliferation, induction of apoptosis, or activation of the immune system. The development and application of blood cancer drugs emphasize precision and individualized therapy, leveraging molecular targets and biomarkers to tailor treatment plans to specific patient populations. Advances in molecular biology, immunology, and genomics continue to expand treatment strategies, improving therapeutic outcomes while reducing adverse effects, and providing patients with more effective and sustainable management of blood cancers.

Blood Cancer Drugs

According to YH Research, the global market for Blood Cancer Drugs should grow from US$ 79325 million in 2025 to US$ 143099 million by 2032, with a CAGR of 8.6% for the period of 2026-2032.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The incidence of blood cancers is steadily increasing, driven by aging populations and environmental factors, providing a growing market demand. The widespread adoption of precision medicine and individualized therapy has made targeted drugs, immunotherapies, and cell-based treatments preferred clinical options. Advancements in novel molecular targeted therapies and immunomodulators offer additional treatment approaches. Support from global healthcare systems for high-value innovative drugs, coupled with expanding insurance coverage, enhances patient access and market potential. Meanwhile, advanced diagnostic technologies enable early detection and disease subtyping, further increasing drug utilization and market size. Blood cancer drug development is costly, time-consuming, and carries high failure risks, creating significant entry barriers. Some novel therapies are constrained by complex manufacturing processes and stringent quality control, leading to production and supply chain risks. High drug costs and healthcare reimbursement policies may limit market access and profitability. Clinical application requires skilled physicians and optimized treatment plans, increasing education and promotion costs. Additionally, drug resistance and potential side effects during therapy can affect long-term market performance. Clinical demand is trending toward precision, personalization, and combination therapies. Patients and physicians increasingly value efficacy, safety, and quality of life, driving demand for low-toxicity drugs and combination regimens. Expansion of primary care and specialty centers broadens the application settings, requiring more convenient preparation and administration. As individualized treatment strategies become more widespread, gene profiling and molecular target-guided therapy are emerging as market trends, promoting diversity and differentiation in blood cancer drug offerings. Upstream materials for blood cancer drugs mainly include active pharmaceutical ingredients, chemical synthesis precursors, biological cell lines, and delivery or sustained-release materials. The active ingredients directly determine efficacy and therapeutic options, while the purity and controllability of chemical and biological materials are critical for product safety and consistency. Complex manufacturing processes and strict quality control standards pose supply chain stability challenges. With advances in biopharmaceutical and synthetic technologies, localization of key raw materials is accelerating, though stringent requirements for batch consistency and process optimization remain.

This report studies and analyses global Blood Cancer Drugs status and future trends, to help determine the Blood Cancer Drugs market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Blood Cancer Drugs, and provides market size (US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Blood Cancer Drugs market size, history data 2021-2025, and forecast data 2026 -2032, (US$ million)
(2) Global Blood Cancer Drugs by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(3) Japan Blood Cancer Drugs by company, revenue, market share and industry ranking 2021-2026, (US$ million)
(4) Global Blood Cancer Drugs key consuming regions, consumption value and demand structure
(5) Blood Cancer Drugs industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Bristol-Myers Squibb
    Johnson & Johnson
    AbbVie
    Novartis
    Roche
    Amgen
    Takeda
    Pfizer
    AstraZeneca
    Gilead Sciences
    Sanofi
    Incyte Corporation
    BeiGene
    Astellas Pharma

Market segment by Type, covers
    Targeted Therapy
    Chemotherapy
    Immunotherapy
    Other

Market segment by Route of Administration, covers
    Oral
    Injection
    Others

Market segment by Sales Channel, covers
    Hospital
    Clinic
    Other

Market segment by Application, can be divided into
    Leukemia
    lymphoma
    Multiple Myeloma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Blood Cancer Drugs product scope, global consumption value, Japan consumption value, development opportunities, challenges, trends, and policies
Chapter 2: Global Blood Cancer Drugs market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 3: Japan Blood Cancer Drugs market share and ranking of major manufacturers, revenue, 2021-2026
Chapter 4: Blood Cancer Drugs industry chain, upstream, medium-stream, and downstream
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2021-2032
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2021-2032
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin
Chapter 10: Conclusions